UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin

Harvey, RD; Aransay, NR; Isambert, N; Lee, J-S; Arkenau, T; Vansteenkiste, J; Dickinson, PA; ... Vishwanathan, K; + view all (2018) Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. British Journal of Clinical Pharmacology , 84 (12) pp. 2877-2888. 10.1111/bcp.13753. Green open access

[thumbnail of Arkenau Harvey_Osi_Manuscript_BJCP_17.05.2018_clean.pdf]
Preview
Text
Arkenau Harvey_Osi_Manuscript_BJCP_17.05.2018_clean.pdf - Accepted Version

Download (470kB) | Preview

Abstract

Aim We report on two Phase 1, open‐label, single‐arm studies assessing the effect of osimertinib on simvastatin (CYP3A substrate) and rosuvastatin (breast cancer resistance protein substrate [BCRP] substrate) exposure in patients with advanced epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer who have progressed after treatment with an EGFR tyrosine kinase inhibitor, to determine, upon coadministration, whether osimertinib could affect the exposure of these agents. Methods Fifty‐two patients in the CYP3A study (pharmacokinetic [PK] analysis, n = 49), and 44 patients in the BCRP study were dosed (PK analysis, n = 44). In the CYP3A study, patients received single doses of simvastatin 40 mg on Days 1 and 31, and osimertinib 80 mg once daily on Days 3–32. In the BCRP study, single doses of rosuvastatin 20 mg were given on Days 1 and 32, and osimertinib 80 mg once daily on Days 4–34. Results Geometric least squares mean (GLSM) ratios (90% confidence intervals) of simvastatin plus osimertinib for area under the plasma concentration–time curves from zero to infinity (AUC) were 91% (77–108): entirely contained within the predefined no relevant effect limits, and Cmax of 77% (63, 94) which was not contained within the limits. GLSM ratios of rosuvastatin plus osimertinib for AUC were 135% (115–157) and Cmax were 172 (146, 203): outside the no relevant effect limits. Conclusions Osimertinib is unlikely to have any clinically relevant interaction with CYP3A substrates and has a weak inhibitory effect on BCRP. No new safety concerns were identified in either study.

Type: Article
Title: Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/bcp.13753
Publisher version: https://doi.org/10.1111/bcp.13753
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: CYP3A, BCRP, NSCLC, osimertinib
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: https://discovery.ucl.ac.uk/id/eprint/10073236
Downloads since deposit
143Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item